Madrigal Pharmaceuticals Management
Management criteria checks 3/4
Madrigal Pharmaceuticals' CEO is Bill Sibold, appointed in Sep 2023, has a tenure of 2.33 years. total yearly compensation is $12.21M, comprised of 7.3% salary and 92.7% bonuses, including company stock and options. directly owns 0.45% of the company’s shares, worth $57.38M. The average tenure of the management team and the board of directors is 2.1 years and 2.6 years respectively.
Key information
Bill Sibold
Chief executive officer
US$12.2m
Total compensation
| CEO salary percentage | 7.28% |
| CEO tenure | 2.3yrs |
| CEO ownership | 0.5% |
| Management average tenure | 2.1yrs |
| Board average tenure | 2.6yrs |
Recent management updates
Recent updates
Madrigal Pharmaceuticals: My Take On Prospects For 2026 Leads To Rating Downgrade
Jan 03Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) 26% Price Boost Is Out Of Tune With Revenues
Nov 12
Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) 30% Price Boost Is Out Of Tune With Revenues
Aug 22Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically
Aug 13Earnings Beat: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 08Earnings Beat: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
May 04
FDA Approval Will Expand MASH Treatment Market Reach
First FDA-approved MASH treatment and strong U.S. market launch position Madrigal Pharmaceuticals for significant revenue growth.Madrigal Pharmaceuticals Q4 Earnings Review: Strong Quarter, Even Stronger Outlook
Feb 26Is Madrigal Pharmaceuticals (NASDAQ:MDGL) Using Debt Sensibly?
Feb 19Madrigal Pharmaceuticals Rezdiffra Vies For Blockbuster Status In MASH
Jan 19Fast Drug Launch For Madrigal Pharmaceuticals Brings Buyout Discussion
Jan 09Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion
Nov 03Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings
Oct 24While Madrigal's Rezdiffra Impresses, Great Uncertainties Loom In MASH Market
Aug 08Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long
Jun 09Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
Apr 24Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge
Mar 15Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential
Feb 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$289m |
| Jun 30 2025 | n/a | n/a | -US$282m |
| Mar 31 2025 | n/a | n/a | -US$392m |
| Dec 31 2024 | US$12m | US$890k | -US$466m |
| Sep 30 2024 | n/a | n/a | -US$519m |
| Jun 30 2024 | n/a | n/a | -US$510m |
| Mar 31 2024 | n/a | n/a | -US$444m |
| Dec 31 2023 | US$33m | US$275k | -US$374m |
Compensation vs Market: Bill's total compensation ($USD12.21M) is about average for companies of similar size in the US market ($USD13.27M).
Compensation vs Earnings: Bill's compensation has been consistent with company performance over the past year.
CEO
Bill Sibold (59 yo)
Mr. William J. Sibold, also known as Bill, serves as Chief Executive Officer, President and Director at Madrigal Pharmaceuticals, Inc. since September 8, 2023. Mr. Sibold joined Madrigal Pharmaceuticals, I...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 2.3yrs | US$12.21m | 0.45% $ 57.4m | |
| Founder | 14.3yrs | US$5.97m | 1.92% $ 243.8m | |
| Executive VP & CFO | 1.8yrs | US$8.84m | 0.046% $ 5.8m | |
| Executive VP | 1.4yrs | US$4.68m | 0% $ 0 | |
| Executive VP & Chief Commercial Officer | 2.2yrs | US$3.95m | 0% $ 0 | |
| Executive Vice President of Business Planning & Operations | 1.3yrs | no data | no data | |
| Executive VP & Chief Information Officer | 2.2yrs | no data | no data | |
| Chief Investor Relations Officer | 2yrs | no data | no data | |
| Executive VP & Chief Human Resources Officer | 2yrs | no data | no data | |
| Senior Vice President of Clinical & Technical Operations | no data | no data | no data | |
| Senior Vice President of Clinical Management | no data | no data | no data | |
| Chief Pharmaceutical Development Officer | 4.4yrs | no data | 0.025% $ 3.2m |
Experienced Management: MDGL's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 2.3yrs | US$12.21m | 0.45% $ 57.4m | |
| Founder | 9.5yrs | US$5.97m | 1.92% $ 243.8m | |
| Independent Chairman of the Board | 2.6yrs | US$484.89k | 0.014% $ 1.7m | |
| Independent Director | less than a year | no data | no data | |
| Director | 9.5yrs | US$508.89k | 0.73% $ 92.1m | |
| Independent Director | 9.4yrs | US$483.89k | 0.090% $ 11.4m | |
| Independent Director | 6.6yrs | US$464.89k | 0.0053% $ 667.9k | |
| Director | less than a year | no data | no data | |
| Independent Director | 2.6yrs | US$483.89k | 0.014% $ 1.7m |
Experienced Board: MDGL's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/07 18:52 |
| End of Day Share Price | 2026/01/07 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Madrigal Pharmaceuticals, Inc. is covered by 29 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Luchini | BMO Capital Markets Equity Research |
| Jason Zemansky | BofA Global Research |
| Alexandria Hammond | BofA Global Research |